HOW SCHIZOPHRENIC-PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS

被引：5
|
作者：
DENCKER, SJ [1 ]
FRANKENBERG, K [1 ]
LEPP, M [1 ]
LINDBERG, D [1 ]
MALM, U [1 ]
机构：
[1] UNIV GOTHENBURG,INST PSYCHOL,S-40033 GOTHENBURG 33,SWEDEN
来源：
ACTA PSYCHIATRICA SCANDINAVICA | 1978年 / 57卷 / 02期
关键词：
D O I：
10.1111/j.1600-0447.1978.tb06879.x
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：115 / 123
页数：9
相关论文
共 50 条
  • [21] EFFECTS OF NEUROLEPTICS ON ELECTRODERMAL ACTIVITY IN SCHIZOPHRENIC-PATIENTS - A REVIEW
    SCHNUR, DB
    PSYCHOPHARMACOLOGY, 1990, 102 (04) : 429 - 437
  • [22] AN OPEN TRIAL OF BUSPIRONE ADDED TO NEUROLEPTICS IN SCHIZOPHRENIC-PATIENTS
    GOFF, DC
    MIDHA, KK
    BROTMAN, AW
    MCCORMICK, S
    WAITES, M
    AMICO, ET
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1991, 11 (03) : 193 - 197
  • [23] CERTAIN NEUROLEPTICS REDUCE BONE MINERALIZATION IN SCHIZOPHRENIC-PATIENTS
    HIGUCHI, T
    KOMODA, T
    SUGISHITA, M
    YAMAZAKI, J
    MIURA, M
    SAKAGISHI, Y
    YAMAUCHI, T
    NEUROPSYCHOBIOLOGY, 1987, 18 (04) : 185 - 188
  • [24] CHANGES IN THE HOSTILITY OF SCHIZOPHRENIC-PATIENTS DURING TREATMENT
    TSIANTIS, J
    BLACKBURN, IM
    LYKETSOS, GC
    BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1981, 54 (SEP): : 251 - 258
  • [25] INFLUENCE OF MODITEN-DEPOT TREATMENT ON DURATION AND QUALITY OF REMISSIONS IN SCHIZOPHRENIC-PATIENTS
    VOVIN, RY
    GUROVICH, IY
    ERYSHEV, OF
    ZAITSEV, SG
    MAGALIF, AY
    NIKITINA, GF
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 1977, 77 (05): : 743 - 749
  • [26] THE PROGNOSTIC VALUE OF THE EARLY RESPONSE OF SCHIZOPHRENIC-PATIENTS TO NEUROLEPTICS CONCERNING THE FOLLOWING COURSE OF TREATMENT
    MOLLER, HJ
    KISSLING, W
    VONZERSSEN, D
    PHARMACOPSYCHIATRIA, 1983, 16 (02): : 46 - 49
  • [27] ENDOCRINE RESPONSES TO TRYPTOPHAN INFUSION IN SCHIZOPHRENIC-PATIENTS TREATED WITH NEUROLEPTICS
    KOLAKOWSKA, T
    COWEN, PJ
    MURDOCK, P
    PSYCHONEUROENDOCRINOLOGY, 1987, 12 (03) : 193 - 202
  • [28] Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics
    Demovsek, MZ
    Rupel, VP
    Rebolj, M
    Tavcar, R
    EUROPEAN PSYCHIATRY, 2001, 16 (08) : 474 - 482
  • [29] THE BIOAVAILABILITY AND PHARMACOKINETICS OF ORAL AND DEPOT INTRAMUSCULAR HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS
    NAYAK, RK
    DOOSE, DR
    NAIR, NPV
    JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (02): : 144 - 150
  • [30] FAMILY RESISTANCE TO CHANGE IN SCHIZOPHRENIC-PATIENTS
    PAUL, NL
    GROSSER, GH
    FAMILY PROCESS, 1964, 3 (02) : 377 - 401
12345